Silence Therapeutics Plc Stock Price, News & Analysis

Silence Therapeutics plc (NASDAQ: SLN) will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2 at 3:30 p.m. ET. This event highlights Silence's commitment to innovative biotechnology aimed at silencing diseases through precision-engineered medicines. The presentation will be available via a live webcast on the Company’s website, with an archived replay accessible afterward. Silence Therapeutics specializes in RNA interference to develop medicines targeting genetic expressions involved in disease pathologies. Notable product candidates include SLN360 for reducing cardiovascular risk and SLN124 for hematological disorders. The Company collaborates with leading pharmaceutical companies like AstraZeneca and Mallinckrodt Pharmaceuticals.

Silence Therapeutics, a biotechnology company, announced the publication of preclinical data in the journal Blood linking iron regulation to polycythemia vera (PV) and supporting the therapeutic potential of SLN124. The authors, including researchers from WEHI, found variants of the iron-regulating gene HFE in a study of 440 PV cases versus over 400,000 controls. The findings suggest SLN124, an siRNA targeting TMPRSS6, may help control red blood cell production in PV by increasing hepcidin levels. Currently undergoing SANRECO phase 1/2 trials, SLN124 has rare pediatric disease, orphan drug, and FDA Fast Track designations for PV.

Silence Therapeutics plc (NASDAQ: SLN) announces management's participation in a virtual fireside chat at Guggenheim’s Genomic Medicines and Rare Disease Days on April 4th, 2023, at 2:10 p.m. ET. A live webcast will be accessible through the Investors section of Silence's website, with an archived replay available post-conference. Silence Therapeutics focuses on developing innovative medicines using RNA interference (RNAi) to target disease-related genes. Notable products include SLN360 for cardiovascular risk and SLN124 for hematological diseases. Collaborations with AstraZeneca and others enhance Silence’s research capabilities.

Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has announced the appointment of Barbara A. Ruskin, Ph.D, J.D., to its Board of Directors, expanding the board to nine members. Dr. Ruskin, who has over 25 years of experience in life sciences and intellectual property law, previously served as Chief Intellectual Property and Innovation Officer at Silence Therapeutics (OTC: SLNCF). Her background includes advising pharmaceutical companies and managing patent portfolios for major biotech firms. The company is focused on developing non-addictive pain management products and is seeking FDA approval for its candidates.